Semaglutide
Ozempic · Wegovy · Rybelsus · NN9535 · NN9924 (oral)
Reviewed by the BestHealingPeptides Editorial Team ·
On this page
What is semaglutide, and is it a peptide?
Semaglutide is a peptide medicine: a linear chain of 31 amino acids with an attached fatty-acid chain, acting as a GLP-1 receptor agonist (a GLP-1 analogue with 94% sequence homology to human GLP-1). In the UK it is the active substance in the prescription only medicines Ozempic and Rybelsus (type 2 diabetes) and Wegovy (weight management, among other indications).
Sources: PubChem compound 56843331; Ozempic SmPC (emc)
Sourced facts at a glance
- Structure: A polypeptide with a linear sequence of 31 amino acids joined by peptide linkages, also classed as a lipopeptide. Molecular formula C187H291N45O59; molecular weight 4114 g/mol. (PubChem compound 56843331)
- Relationship to GLP-1: A GLP-1 analogue with 94% sequence homology to human GLP-1, produced in Saccharomyces cerevisiae cells by recombinant DNA technology; elimination half-life of approximately 1 week. (Ozempic SmPC (emc))
- UK brands and licensed indications: Ozempic and Rybelsus are indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, for weight management in adults with a BMI of 30 kg/m2 or more, or 27 to under 30 kg/m2 with at least one weight-related comorbidity; in adolescents aged 12 and over with obesity and body weight above 60 kg; to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; and, with diet and exercise, for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (stages F2 to F3). Wegovy tablets are indicated, with a reduced-calorie diet and increased physical activity, for weight management in adults with a BMI of 30 kg/m2 or more, or 27 to under 30 kg/m2 with at least one weight-related comorbidity. All are listed as prescription only medicines. (Ozempic SmPC; Rybelsus SmPC; Wegovy SmPC; Wegovy tablets SmPC)
- EU marketing authorisations (EMA): Ozempic issued 8 February 2018; Rybelsus issued 3 April 2020; Wegovy issued 6 January 2022. (EMA Ozempic EPAR; EMA Rybelsus EPAR; EMA Wegovy EPAR)
- UK SmPC dates of first authorisation: Wegovy injection: 10 May 2022. Wegovy tablets: 11 June 2026. (Wegovy SmPC; Wegovy tablets SmPC)
- US FDA original approvals: Ozempic 5 December 2017; Rybelsus 20 September 2019; Wegovy 4 June 2021. (Drugs@FDA Ozempic; Drugs@FDA Rybelsus; Drugs@FDA Wegovy)
- Weight-management trial result (STEP 1): In 1,961 adults with overweight or obesity and without diabetes, mean body-weight change at week 68 was -14.9% with once-weekly subcutaneous semaglutide versus -2.4% with placebo, both plus lifestyle intervention. (Wilding et al., NEJM 2021 (PMID 33567185))
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous injection and oral tablets). The most clinically significant GLP-1 receptor agonist of the late 2020s.
Mechanism of action
Yes — Ozempic is a peptide. Its active ingredient, semaglutide, is a synthetic analogue of the human gut hormone GLP-1 (glucagon-like peptide-1), sharing 94% sequence homology with native GLP-1, and it works by selectively binding to and activating the GLP-1 receptor — the same receptor targeted by the natural hormone (UK Summary of Product Characteristics; FDA prescribing information). The peptide backbone is produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology, then chemically modified at amino-acid position 8 to resist degradation by the DPP-4 enzyme and at lysine 26 with a C18 fatty-diacid chain that binds circulating albumin — extending the plasma half-life to roughly one week and enabling once-weekly subcutaneous dosing. Ozempic is MHRA-licensed in the UK for type-2 diabetes; the same molecule, at a higher dose, is licensed as Wegovy for weight management.
Semaglutide is a 31-amino-acid synthetic peptide structurally derived from native human GLP-1 with two engineered modifications that confer dramatic plasma half-life extension and protease resistance. The first modification is substitution of native alanine at position 8 with α-aminoisobutyric acid (Aib), an unnatural amino acid that blocks dipeptidyl peptidase-4 (DPP-4)-mediated cleavage of the N-terminal His-Ala bond — the principal degradation pathway of native GLP-1 (plasma half-life ~2 minutes). The second modification is covalent attachment of a C18 fatty diacid moiety to the ε-amino group of lysine 26 via a γ-glutamic acid and two short polyethylene glycol-like linkers (2xOEG). The fatty diacid chain binds non-covalently but with very high affinity to circulating serum albumin (~67 kDa), shielding the peptide from renal filtration and protease degradation and producing the ~7-day plasma half-life that supports once-weekly subcutaneous dosing.
Mechanistically, semaglutide functions as a full GLP-1 receptor agonist with binding affinity comparable to native GLP-1. The GLP-1R is a 463-residue class B G-protein-coupled receptor expressed prominently on pancreatic β-cells (the principal therapeutic target), pancreatic α-cells, intestinal mucosa, central neurons (hypothalamic arcuate nucleus, area postrema), peripheral vagal neurons, vascular smooth muscle, and other tissues. Receptor activation triggers Gαs/adenylate cyclase signalling, raising intracellular cAMP and activating both protein kinase A (PKA) and the Epac2 guanine nucleotide exchange factor.
The principal therapeutic effects emerge from receptor activation in distinct tissues. β-cell GLP-1R activation potentiates glucose-stimulated insulin secretion in a strictly glucose-dependent manner — at low glucose concentrations the insulinotropic signal is minimal, which provides the favourable hypoglycaemia profile that distinguishes incretin-based therapy from sulphonylureas. α-cell GLP-1R activation suppresses glucagon secretion, providing a complementary glucose-lowering mechanism. Central GLP-1R activation in the hypothalamic arcuate nucleus and brainstem area postrema drives appetite suppression, early satiety, and reduced food intake — the principal mechanism behind the dramatic weight-loss efficacy seen at higher dose tiers (Wegovy). Peripheral effects include slowed gastric emptying (which flattens the postprandial glucose excursion), modest blood pressure reduction, and emerging neuroprotective effects.
The oral semaglutide formulations (Rybelsus and Wegovy tablets) address the standard gastric peptide-degradation problem through co-formulation with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), an absorption enhancer that temporarily raises gastric pH and protects semaglutide from peptidase degradation during a narrow gastric absorption window. Oral bioavailability is materially lower than subcutaneous (~1% versus near-complete), but the SNAC platform enables daily oral dosing as an alternative to weekly injection. Per section 5.2 of the Rybelsus SmPC, two formulations of the tablets exist, 1.5 mg, 4 mg and 9 mg (round tablets) and 3 mg, 7 mg and 14 mg (oval tablets); bioequivalent doses of the two formulations are given in the SmPC, and both have live UK SmPCs on the emc. The phase 3a PIONEER trials used the 3, 7 and 14 mg tablets.
Downstream metabolic effects of sustained GLP-1R activation produce the characteristic semaglutide phenotype: 1-2% absolute HbA1c reduction in type-2 diabetes, 6-15% body weight reduction (depending on dose and duration), favourable lipid changes, modest blood pressure reduction, and cardiovascular event reduction documented in dedicated outcome trials (SUSTAIN-6, PIONEER, STEP, SELECT). The strictly glucose-dependent insulinotropic profile means severe hypoglycaemia is rare in monotherapy use; risk rises with concurrent sulphonylurea or insulin therapy.
Semaglutide 2.4 mg subcutaneous weekly produces 14.9% mean body weight loss over 68 weeks in non-diabetic adults with obesity (STEP 1, Wilding et al., NEJM 2021) — the largest pharmacological weight-loss effect documented in a peer-reviewed trial at the time of publication, transforming the regulatory and commercial landscape of obesity therapeutics.
— Notable finding
Development history
Semaglutide was developed by Novo Nordisk through systematic medicinal chemistry building on the company's experience with liraglutide, the first commercially successful long-acting GLP-1R agonist (FDA-approved 2010, MHRA-licensed shortly after). The development goal was once-weekly rather than once-daily dosing through extended fatty-acid-acylation chemistry, which became the principal differentiator of semaglutide over liraglutide and exenatide. Phase II development confirmed the once-weekly dosing pharmacology; Phase III SUSTAIN programme (multiple trials across type-2 diabetes settings) established efficacy and safety, supporting first FDA approval (Ozempic, December 2017) and MHRA marketing authorisation shortly after.
The SUSTAIN-6 cardiovascular outcome trial (Marso et al., NEJM 2016) — published before regulatory approval — established MACE reduction with semaglutide in type-2 diabetes patients with established cardiovascular disease, paralleling the LEADER trial results for liraglutide. Cardiovascular benefit at the class level (GLP-1R agonists) transformed the regulatory and reimbursement landscape, supporting broader use beyond pure glycaemic control.
The weight-management indication emerged from observation that the higher dose tiers used in some Phase III trials produced substantial weight loss beyond the glycaemic control. The STEP programme (multiple Phase III trials, 2018-2021) tested semaglutide 2.4 mg subcutaneous weekly in obesity without diabetes, demonstrating ~15% mean body weight reduction over 68 weeks — substantially larger than any prior pharmacological weight-loss intervention. Wegovy received FDA approval in June 2021 and MHRA marketing authorisation in 2022, generating the explosive 'GLP-1 weight loss' commercial and cultural phenomenon of 2023-2025. UK supply constraints were severe through 2023-2024, partially resolved by 2025-2026.
The oral semaglutide formulation (Rybelsus) received FDA approval in September 2019 and MHRA marketing authorisation in 2020 as the first orally bioavailable GLP-1R agonist, enabled by the SNAC absorption-enhancer platform licensed from Emisphere Technologies. The SELECT cardiovascular outcome trial (2023) extended cardiovascular benefit to non-diabetic obese subjects, further broadening the population eligible for chronic GLP-1R agonist therapy.
In the UK in 2025-2026, semaglutide is widely prescribed for type-2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), with NICE technology appraisal guidance supporting NHS prescription within specified eligibility criteria. The compound has materially altered the standard-of-care landscape for both conditions.
Licensed dose regimens
The regimens below are summarised from the UK Summaries of Product Characteristics. They are not a dosing recommendation; follow your prescriber.
| Indication | Route | Regimen | Note |
|---|---|---|---|
| Type-2 diabetes (Ozempic, MHRA-licensed) | Subcutaneous, once weekly | Start 0.25 mg/week × 4 weeks; increase to 0.5 mg/week; after at least 4 weeks the dose can be increased to 1 mg/week, and after at least 4 weeks on 1 mg to 2 mg/week | Ozempic SmPC section 4.2. 0.25 mg is not a maintenance dose; weekly doses above 2 mg are not recommended. NICE NG28 recommends offering subcutaneous semaglutide, up to 1 mg once a week, to adults with type 2 diabetes and atherosclerotic cardiovascular disease. |
| Chronic weight management (Wegovy, MHRA-licensed) | Subcutaneous, once weekly | Start 0.25 mg/week × 4 weeks; escalate over 16 weeks (0.5, 1, 1.7 mg) to 2.4 mg/week maintenance; if needed in adults with obesity, 7.2 mg/week after a minimum of 4 weeks on 2.4 mg | Wegovy injection SmPC section 4.2: the dose should be escalated over a 16-week period to reduce the likelihood of gastrointestinal symptoms. 2.4 mg is the dose studied in STEP 1 (~15% mean weight loss). |
| Chronic weight management (Wegovy tablets, MHRA-licensed) | Oral tablet, once daily on empty stomach | Start 1.5 mg/day × 1 month; then 4 mg, 9 mg and 25 mg/day with a minimum of 1 month at each dose; 25 mg/day is the maintenance dose and the maximum | Wegovy tablets SmPC section 4.2: empty stomach after at least 8 hours fasting, swallowed whole with a sip of water (up to 120 mL), then wait at least 30 minutes before eating, drinking or taking other oral medicines. |
| Type-2 diabetes (Rybelsus, MHRA-licensed) | Oral tablet, once daily on empty stomach | 1.5 mg/day × 1 month, then 4 mg/day; after at least 1 month on 4 mg, 9 mg/day if needed (maximum 9 mg). The 3, 7 and 14 mg oval-tablet formulation follows the same steps (3 mg × 1 month, then 7 mg, then 14 mg; maximum 14 mg) | Rybelsus SmPC: two bioequivalent formulations are authorised, 1.5/4/9 mg (round) and 3/7/14 mg (oval) (section 5.2). Section 4.2: take on an empty stomach after a fasting period of at least 8 hours, swallow whole with a sip of water (up to 120 mL), then wait at least 30 minutes before eating, drinking or taking other oral medicines; waiting less than 30 minutes decreases absorption. |
Reconstitution & storage
Summarised studies
| Year | Model | Outcome | Citation | Source |
|---|---|---|---|---|
| 2016 | Type-2 diabetes adults with elevated cardiovascular risk, RCT | MACE reduction HR 0.74; significant nonfatal stroke reduction; transient eye-complication signal | Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834-1844 | PMID 27633186 |
| 2021 | Non-diabetic adults with obesity, RCT | 14.9% mean weight loss versus 2.4% placebo; favourable cardiometabolic profile | Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002 | PMID 33567185 |
| 2023 | Non-diabetic adults with obesity and CVD, RCT | 20% MACE reduction; cardiovascular mortality reduction | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023;389(24):2221-2232 | PMID 37952131 |
| 2019 | Type-2 diabetes adults with elevated cardiovascular risk, RCT | MACE non-inferiority; trend toward benefit | Husain M, Birkenfeld AL, Donsmark M, et al. N Engl J Med. 2019;381(9):841-851 | PMID 31185157 |
| 2024 | Network meta-analyses | Established semaglutide as preferred GLP-1R agonist of the late-2020s era for combined glycaemia and weight outcomes | Multiple network meta-analyses and indirect comparisons across the SUSTAIN, AWARD, LEAD, and DURATION programmes | — |
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)
Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834-1844 · 2016 · PMID 27633186
Landmark cardiovascular outcomes trial demonstrating MACE reduction (HR 0.74) with semaglutide 0.5 or 1.0 mg subcutaneous weekly versus placebo in 3,297 type-2 diabetes patients with established cardiovascular disease or cardiovascular risk factors over 104 weeks. Established cardiovascular benefit beyond glycaemic control.
PubMedOnce-weekly semaglutide in adults with overweight or obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002 · 2021 · PMID 33567185
Pivotal weight-management trial of semaglutide 2.4 mg subcutaneous weekly versus placebo in 1,961 non-diabetic adults with BMI ≥30 (or ≥27 with comorbidity) over 68 weeks. Mean weight loss 14.9% versus 2.4% placebo — the largest pharmacological weight-loss effect documented in a peer-reviewed trial at the time.
PubMedSemaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023;389(24):2221-2232 · 2023 · PMID 37952131
Cardiovascular outcomes trial of semaglutide 2.4 mg subcutaneous weekly in 17,604 non-diabetic adults with BMI ≥27 and established cardiovascular disease. MACE reduction 20% (HR 0.80) over mean 39.8 months follow-up, establishing cardiovascular benefit of semaglutide in obesity without diabetes.
PubMedOral semaglutide and cardiovascular outcomes in type 2 diabetes (PIONEER 6)
Husain M, Birkenfeld AL, Donsmark M, et al. N Engl J Med. 2019;381(9):841-851 · 2019 · PMID 31185157
Cardiovascular outcomes trial of oral semaglutide 14 mg daily versus placebo in 3,183 type-2 diabetes patients with cardiovascular risk. Non-inferiority for MACE established with point estimate suggesting benefit (HR 0.79). The 14 mg oval tablet used in the trial is bioequivalent to the 9 mg round tablet (Rybelsus SmPC section 5.2).
PubMedComparative efficacy and safety of GLP-1 receptor agonists in adults with type 2 diabetes
Multiple network meta-analyses and indirect comparisons across the SUSTAIN, AWARD, LEAD, and DURATION programmes · 2024
Comparative effectiveness analyses positioning semaglutide as more efficacious than liraglutide, exenatide, lixisenatide, and dulaglutide for glycaemic and weight outcomes in type-2 diabetes, with tirzepatide subsequently surpassing semaglutide on weight-loss endpoints.
Safety profile
Semaglutide has the largest published clinical-trial safety dataset of any peptide drug, accumulated through the SUSTAIN, PIONEER, STEP, SELECT, and post-marketing surveillance programmes spanning over 50,000 trial participants and millions of post-marketing exposures. The principal documented adverse events are gastrointestinal: nausea (15-44% depending on dose), vomiting (5-25%), diarrhoea (10-30%), and constipation (15-25%). These are dose-dependent, most prominent during dose escalation, and generally mild-to-moderate; they account for the majority of treatment discontinuations. Dose-titration protocols (starting at 0.25 mg subcutaneous weekly, escalating to therapeutic doses over 16+ weeks) substantially mitigate the GI symptom burden.
The glucose-dependent insulinotropic mechanism produces a favourable hypoglycaemia profile in monotherapy. Severe hypoglycaemia is rare when semaglutide is used alone or with metformin; risk rises materially with concurrent sulphonylurea or insulin therapy, where dose reductions of the concurrent agents are recommended.
Less common but clinically significant adverse events documented in the published trials include acute pancreatitis (uncommon, with absolute rates of 0.3-0.5% but elevated relative to placebo in some analyses), acute biliary disease (cholecystitis and cholelithiasis, related to rapid weight loss and GLP-1 effects on biliary motility), modest heart rate elevation (~2-5 bpm), injection-site reactions for the subcutaneous formulations, and rare reports of diabetic retinopathy progression in patients with pre-existing severe retinopathy.
The theoretical thyroid C-cell carcinoma concern carried forward from earlier GLP-1R agonists (liraglutide, exenatide) — based on rodent thyroid C-cell hyperplasia in chronic toxicity studies — is reflected in the FDA boxed warning. The UK Summaries of Product Characteristics (Ozempic, Wegovy, Rybelsus) list hypersensitivity as the only contraindication in section 4.3; the rodent thyroid C-cell tumours are described as a GLP-1 receptor agonist class effect in section 5.3, which says their relevance for humans is considered to be low, but cannot be completely excluded. Large epidemiological analyses have not confirmed an increased medullary thyroid carcinoma risk in GLP-1R-agonist-treated patients.
The SELECT and STEP programmes documented favourable cardiovascular and renal safety profiles, with the SUSTAIN-6 and SELECT trials demonstrating MACE reduction in cardiovascular-risk populations. Mood and suicidality concerns raised in 2023-2024 by isolated case reports have been examined in formal regulatory reviews (FDA, EMA, MHRA) which concluded that the available evidence does not establish a causal association between semaglutide therapy and suicidality, though monitoring continues.
Anti-semaglutide antibodies develop in a small proportion of treated patients but are generally non-neutralising and have not produced documented loss of efficacy.
Reported contraindications & cautions
- Hypersensitivity to semaglutide or any excipient (the only contraindication listed in SmPC section 4.3)
- Pregnancy: should not be used; discontinue if pregnancy occurs, and at least 2 months before a planned pregnancy because of the long half-life (SmPC section 4.6)
- Breast-feeding: should not be used (SmPC section 4.6)
- Not a substitute for insulin (Ozempic and Wegovy SmPCs, section 4.4); the Ozempic and Rybelsus SmPCs add that semaglutide should not be used in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
- Gastroparesis: more serious or severe gastrointestinal adverse events may occur; use with caution, and not recommended if severe (SmPC section 4.4)
- History of pancreatitis: not studied, use with caution; if acute pancreatitis is suspected stop treatment, and do not restart if confirmed (SmPC section 4.4)
- Rodent thyroid C-cell tumours are a GLP-1 receptor agonist class effect (SmPC section 5.3) and the FDA label carries a boxed warning; history of medullary thyroid carcinoma or MEN-2 is not a listed UK SmPC contraindication, so discuss it with the prescriber
Known interactions (product label)
- Sulphonylureas and insulin: increased hypoglycaemia risk; dose reduction of concurrent agent recommended.
- Warfarin and other oral medications: slowed gastric emptying may affect absorption kinetics; monitor INR and other drug-effect markers.
- Oral semaglutide (Rybelsus, Wegovy tablets): must be taken 30 minutes before food, drink, or other oral medications to enable SNAC-mediated absorption; failure to follow timing reduces bioavailability.
- Levothyroxine and other narrow-therapeutic-index oral drugs: gastric emptying effects may modestly alter absorption.
- No CYP-mediated drug-drug interactions are clinically significant — semaglutide is metabolised by proteolytic peptidases rather than CYP enzymes.
UK regulatory status
Semaglutide is fully MHRA-licensed in the United Kingdom across several products and indications. Ozempic (semaglutide 0.5, 1 and 2 mg subcutaneous weekly) is licensed for type-2 diabetes mellitus in adults. Wegovy injection (semaglutide 2.4 mg subcutaneous weekly, reached by escalating the dose over 16 weeks; 7.2 mg weekly can be used after at least 4 weeks on 2.4 mg for weight management in adults with obesity) and Wegovy tablets (semaglutide 1.5, 4, 9 and 25 mg once daily) are licensed for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity. Rybelsus tablets are licensed for type-2 diabetes mellitus in adults; two bioequivalent formulations are authorised, 1.5, 4 and 9 mg (round tablets) and 3, 7 and 14 mg (oval tablets).
NHS prescription of Wegovy for obesity is supported by NICE technology appraisal guidance TA875 (semaglutide for managing overweight and obesity) within specified eligibility criteria, while for type-2 diabetes NICE guideline NG28 (type 2 diabetes in adults: management, updated February 2026) recommends offering subcutaneous semaglutide (Ozempic), up to 1 mg once a week, to adults with type 2 diabetes and atherosclerotic cardiovascular disease (recommendations 1.15.1, 1.15.2 and 1.27.1); for some other groups, such as adults with early-onset type 2 diabetes or with obesity who need further medicines, it recommends considering a GLP-1 receptor agonist or tirzepatide. NHS supply of Wegovy is restricted to specialist obesity services or under shared-care arrangements; private prescription is also available.
Semaglutide is a Prescription Only Medicine (POM) under the Human Medicines Regulations 2012. Supply or possession for human use outside a valid prescription is regulated. There is no controlled-drug classification under the Misuse of Drugs Act 1971. Unauthorised online supply of unlicensed or counterfeit semaglutide has been a recurring MHRA enforcement concern, particularly during the 2023-2024 supply shortages; the MHRA has published multiple warnings about counterfeit Ozempic and Wegovy entering the UK supply chain through unauthorised channels.
Semaglutide is not on the WADA Prohibited List as of 2026. Recreational athletic use raises distinct ethical and safety considerations but is not currently a doping violation.
Frequently asked questions
What is a semaglutide peptide, and how many amino acids does it contain?
What are the key facts about semaglutide?
Are semaglutide peptides sold as research chemicals the same as Ozempic or Wegovy?
Is Ozempic a peptide?
What is semaglutide made of?
How is Ozempic different from natural GLP-1?
What is the difference between Ozempic, Wegovy, and Rybelsus?
Is semaglutide available on the NHS?
Why does semaglutide cause weight loss?
Does semaglutide cause hypoglycaemia?
What are the common side effects?
Is semaglutide prohibited in sport?
What is the thyroid cancer warning?
When were Ozempic, Wegovy and Rybelsus approved?
Is semaglutide a prescription-only medicine in the UK?
References
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834-1844 (2016). PMID 27633186
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1). Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002 (2021). PMID 33567185
- Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023;389(24):2221-2232 (2023). PMID 37952131
- Oral semaglutide and cardiovascular outcomes in type 2 diabetes (PIONEER 6). Husain M, Birkenfeld AL, Donsmark M, et al. N Engl J Med. 2019;381(9):841-851 (2019). PMID 31185157
- Comparative efficacy and safety of GLP-1 receptor agonists in adults with type 2 diabetes. Multiple network meta-analyses and indirect comparisons across the SUSTAIN, AWARD, LEAD, and DURATION programmes (2024).
- MHRA SmPC: Ozempic (semaglutide) — type 2 diabetes
- MHRA SmPC: Wegovy (semaglutide) — weight management
- MHRA SmPC: Rybelsus (oral semaglutide)
- FDA prescribing information (DailyMed): Ozempic (semaglutide) injection — Description & Mechanism of Action
- NICE TA875 — Wegovy for managing overweight and obesity
- NICE NG28 — Type 2 diabetes in adults: management
- PubChem — Semaglutide (CID 56843331)
- EMA EPAR — Ozempic
- EMA EPAR — Wegovy
- EMA EPAR — Rybelsus
- Drugs@FDA — Ozempic (NDA 209637)
- Drugs@FDA — Rybelsus (NDA 213051)
- Drugs@FDA — Wegovy (NDA 215256)
- Marso et al. 2016 — SUSTAIN-6 (PMID 27633186)
- Wilding et al. 2021 — STEP 1 (PMID 33567185)
- Lincoff et al. 2023 — SELECT (PMID 37952131)
Appears in research stacks
Side-by-side comparisons
Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are the two most clinically significant incretin-pathway peptide drugs of the late 2020s. Both are MHRA-licensed for type-2 diabetes and chronic weight management, both are available as once-weekly subcutaneous injections, both are products of similar peptide-engineering principles (Aib substitution for DPP-4 resistance, fatty-acid acylation for albumin binding). The fundamental pharmacological difference is receptor pharmacology: semaglutide is a selective GLP-1 receptor agonist; tirzepatide adds GIP receptor agonism for dual-receptor pharmacology. Head-to-head trials (SURPASS-2, SURMOUNT-5) confirm tirzepatide produces superior HbA1c reduction and weight loss at the doses tested (semaglutide 1.0 mg in SURPASS-2 and 1.7 or 2.4 mg in SURMOUNT-5).
Semaglutide vs Retatrutide
Semaglutide is the licensed GLP-1 monoagonist that defined the modern incretin weight-loss category; retatrutide is Eli Lilly's investigational triple GLP-1/GIP/glucagon agonist, which produced 25.0% mean weight loss at 12 mg over 80 weeks in the Phase III TRIUMPH-1 trial (NEJM 2026). Both target the incretin pathway but at fundamentally different scales of receptor coverage and development maturity.
Cited in research summaries
Related peptides
Tirzepatide
A dual GIP and GLP-1 receptor agonist: an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding, giving an elimination half-life of approximately 5 days and once-weekly subcutaneous dosing. Licensed in the UK as Mounjaro (KwikPen), a prescription only medicine for type 2 diabetes in adults, adolescents and children aged 10 years and above and for weight management in adults (Zepbound is the US brand only). In the head-to-head SURPASS-2 and SURMOUNT-5 trials tirzepatide produced greater HbA1c reduction and weight loss than semaglutide.
Retatrutide
An Eli Lilly triple agonist of the GLP-1, GIP, and glucagon receptors — an extension of tirzepatide's dual-agonist mechanism with added glucagon-receptor activation. Phase II results (Jastreboff et al., NEJM 2023) showed 24.2% mean body weight loss over 48 weeks at the 12 mg dose, and the Phase III TRIUMPH-1 trial (Jastreboff et al., NEJM 2026) reported 25.0% at 12 mg over 80 weeks versus 3.9% with placebo. Not approved in any jurisdiction as of 29 October 2026; Eli Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027.
MOTS-c
A 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA region of the mitochondrial genome — the first MDP discovered with established metabolic-regulatory function. MOTS-c modulates AMPK signalling and folate cycle methylation, with pre-clinical evidence for effects on insulin sensitivity, exercise capacity, and skeletal-muscle glucose handling. Cross-listed in the metabolic and longevity clusters; not licensed in any jurisdiction.
AOD-9604
A 16-amino-acid C-terminal analogue of human growth hormone, originally investigated for lipolytic activity without IGF-1 effects, and subsequently studied for cartilage repair and post-injury recovery.